Actualités Eulerpool Soligenix

Actualités de l'action Soligenix

Soligenix est suivi par de nombreux journalistes et investisseurs dans le monde. Nous rassemblons ici les dernières actualités concernant Soligenix.

19 mars ·
Benzinga
Soligenix Says Summary Of All Clinical Trials Completed To Date Of Hybryte (Synthetic Hypericin) For Cutaneous T-Cell Lymphoma Has Been Published In The Peer-reviewed Medical Journal Expert Opinion On Investigational Drugs
12 mars ·
Benzinga
Watching Soligenix; Zacks Small-Cap Research Gives Stock $25.00 Price Valuation
10 mars ·
Benzinga
Soligenix's SGX945 (Dusquetide) Receives Promising Innovative Medicine Designation In U.K. For Behçet's Disease
26 février ·
Yahoo
Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behçet's Disease
26 février ·
Benzinga
Soligenix Says EMA COMP Issues Positive Opinion On Orphan Drug Designation Request For SGX945 Dusquetide In Behçet's Disease
24 février ·
Yahoo
Soligenix to Present at BIO Investment & Growth Summit
12 février ·
Yahoo
Soligenix Details Recent Progress and Upcoming Milestones
9 février ·
Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
18 décembre ·
Benzinga
Soligenix Announces Results From Phase 2a Proof Of Concept Study Evaluating SGX945 In Treatment Of Behçet's Disease Published In Rheumatology (Oxford)
5 décembre ·
Yahoo
Soligenix Inc. (NASDAQ: SNGX) Advancing Rare-Disease Therapies Positioned at Pivotal Crossroad
3 décembre ·
Yahoo
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
19 novembre ·
Yahoo
Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
19 novembre ·
Benzinga
Soligenix Completes Planned Enrollment Of 50 Patients Necessary For Interim Analysis In 80 Patient Confirmatory Phase 3 Double-Blind, Placebo-Controlled Study Evaluating HyBryte In CTCL Treatment
7 novembre ·
Benzinga
Soligenix Q3 EPS $(0.58) Misses $(0.56) Estimate
7 octobre ·
Benzinga
Soligenix Reports No Safety Concerns In First DMC Review Of Phase 3 HyBryte Trial For CTCL
26 septembre ·
Benzinga
Soligenix shares are trading lower after the company announced it priced its $7.5 million offering.
23 septembre ·
Yahoo
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
23 septembre ·
Benzinga
Soligenix shares are trading higher after the company appointed former White House economic adviser Tomas J. Philipson as a strategic advisor.
21 août ·
Benzinga
5 Healthcare Stocks On Fire This Week
18 août ·
Benzinga
12 Health Care Stocks Moving In Monday's After-Market Session

Communiqués de presse relatifs à l'action Soligenix

Soligenix publie régulièrement sur son site web des communiqués pertinents pour les investisseurs.

15 novembre •
Soligenix
Soligenix to Receive $1.2 M in Non-Dilutive Funding Through New Jersey Technology Business Tax Certificate Transfer Program
11 novembre •
Soligenix
Investor Summit Group Announces Soligenix, Inc. To Present at Q4 Conference
10 novembre •
Soligenix
Soligenix Announces Recent Accomplishments And Third Quarter 2022 Financial Results
25 octobre •
Soligenix
Soligenix Announces Formation of Psoriasis Medical Advisory Board
20 octobre •
Soligenix
Soligenix Announces Adjournment of Annual Meeting and Information for Reconvened Meeting
17 octobre •
Soligenix
New to The Street to Feature Soligenix Appearances on Its Syndicated Televised Outlets
13 octobre •
Soligenix
Soligenix Enters Q4 With Multiple Catalysts in Play
23 septembre •
Soligenix
Soligenix Announces Partial Adjournment of Annual Meeting and Information for Reconvened Annual Meeting
12 septembre •
Soligenix
FDA Awards $2.6 Million Grant for Expanded Study of Soligenix's Hybryte(TM) for CTCL
8 septembre •
Soligenix
Soligenix to Present at the H.C. Wainwright 24th Annual Global Investment Conference
6 septembre •
Soligenix
U.S. Food and Drug Administration Awards $2.6 Million Orphan Products Development Grant for Expanded Study of HyBryte™ in the Treatment of Cutaneous T-Cell Lymphoma
12 août •
Soligenix
Soligenix Announces Recent Accomplishments And Second Quarter 2022 Financial Results
27 juillet •
Soligenix
Soligenix Receives Agreement from FDA on Initial Pediatric Study Plan for HyBryte™ for the Treatment of Cutaneous T-Cell Lymphoma
26 juillet •
Soligenix
Soligenix's HyBryte(TM) Treatment Now Within Reach for Rare Cancer Patients
25 juillet •
Soligenix
Soligenix Announces Strategic Partnership with SERB Pharmaceuticals to Supply its Novel Ricin Antigen
20 juillet •
Soligenix
HyBryte™ Phase 3 FLASH Study for the Treatment of Cutaneous T-Cell Lymphoma Published in JAMA Dermatology
28 juin •
Soligenix
Soligenix Receives FDA IND Clearance for Phase 2 Clinical Trial of Synthetic Hypericin in the Treatment of Psoriasis
23 juin •
Soligenix
Soligenix Announces Successful Protection using a Bivalent Thermostabilized Filovirus Vaccine
7 juin •
Soligenix
Soligenix Moves Forward with Treatments for Cutaneous T-Cell Lymphoma and Psoriasis
1 juin •
Soligenix
Key Binding Characteristics of Dusquetide to Important Intracellular Protein Identified
23 mai •
Soligenix
Soligenix Receives US Patent Allowance for its Thermostabilized Vaccine Platform
18 mai •
Soligenix
Soligenix to Present at the H.C. Wainwright Global Investment Conference
13 mai •
Soligenix
Soligenix Announces Recent Accomplishments And First Quarter 2022 Financial Results
19 avril •
Soligenix
Soligenix Receives $1.4M in Non-Dilutive Government Funding
29 mars •
Soligenix
Soligenix Announces Recent Accomplishments And Year-End 2021 Financial Results
17 mars •
Soligenix
Soligenix COVID-19 Vaccine, CiVax™, Boosts Neutralizing Activity against SARS-CoV-2, including Delta and Omicron
2 mars •
Soligenix
SG Blocks, Inc. Leads Round of Investment for Moliving, Inc.
2 mars •
Soligenix
Soligenix to Present at the Q1 Virtual Investor Summit
1 mars •
Soligenix
Soligenix, Inc. to Present at the Q1 Virtual Investor Summit
12 janvier •
Soligenix
Soligenix Corporate Update Includes NDA Plans for HyBryte(TM)

Soligenix News 2026

Cette page contient toutes les actualités actuelles, analyses et communiqués de presse pour l'action Soligenix (SNGX, ISIN : US8342236044). Cela inclut les actualités Eulerpool, les analyses d'entreprise et les communiqués de presse officiels. Les données sont mises à jour régulièrement pour fournir aux investisseurs un aperçu complet des derniers développements chez Soligenix.